跳至主要内容
临床试验/NCT04720222
NCT04720222已完成不适用

An Explorative, Monocentric, Feasibility Study to Evaluate the Detectability of the Bladder in Healthy Subjects by Ultrasound Monitoring With the Early TENA Bladder Sensor Prototype

Essity Hygiene and Health AB1 个研究点 分布在 1 个国家目标入组 91 人开始时间: 2021年4月29日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
91
试验地点
1
主要终点
Bladder detectability rate as a function of gender, BMI, age, sensor position, posture and combinations of these variables

研究概览

简要总结

This is an explorative, monocentric, feasibility study to evaluate the detectability of the bladder in healthy subjects by ultrasound monitoring with the early prototype of a future bladder sensor, which is intended for use for an individual suffering from urinary incontinence.

详细描述

The purpose of this clinical investigation with healthy subjects (defined as subjects without urological problems or lower urinary tract symptoms, assured by pre-defined inclusion and exclusion criteria) is to collect raw measurement data of the urinary bladder region of volunteers with the TENA-PROTO1, in multiple postural positions to evaluate the detectability of the bladder in the intended users and to determine the position criteria for the (future) ultrasound sensor on the lower abdomen. Secondarily, this clinical investigation aims to collect data on the adhesive and supportive belt used to fix the transducer assembly to the lower abdomen by the subject. Furthermore, safety of the subjects will be continously documented such as adverse events (AE) and device deficiencies (DD); AEs, Adverse Device Events (ADE), Severe Adverse Events (SAE), Severe Adverse Device effects (SADE), Unanticipated Serious Adverse Device Effects (USADE) and DDs.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Device Feasibility
盲法
None

入排标准

年龄范围
35 Years 至 74 Years(Adult, Older Adult)
性别
All
接受健康志愿者
是

入选标准

  • •Men, women and diverse ≥ 35 and <75 years old
  • •Capability to understand the subject information and to provide conscious informed consent
  • •Signed informed consent for study participation and data protection regulations
  • •All subjects with childbearing potential must either be surgically sterile (hysterectomy or tubal ligation) or agree to use a reliable method of contraception with a failure rate of a Pearl-Index less than 1% per year when used consistently and correctly such as implants, injectables, combined oral contraceptives, some intra uterine devices, sexual abstinence or vasectomized partner for at least 4 weeks
  • •Willingness to conduct a urine pregnancy test for all subjects with childbearing potential
  • •BMI ≥18.5 kg/m² and <40 kg/m²
  • •Capability and willingness to follow the following requirements: protocol, current hygiene concept and laboratory safety

排除标准

  • •Subjects with urological problems or lower urinary tract symptoms
  • •Subjects with breached skin, open wounds, sutures or major scar tissue in the suprapubic region.
  • •Subjects with active implants that can be affected by electromagnetic interference (e.g. pacemaker)
  • •Subjects with symptoms of constipation or diarrhea
  • •Subjects who are pregnant or breast feeding
  • •Known allergies or intolerances to one or several components of the study product
  • •Alcohol abuse as reported by subject and/ or suspected by investigator that impacts capability to understand the subject information and to provide conscious informed consent in the discretion of the investigator / study personnel
  • •Drug abuse as reported by subject and/ or suspected by investigator that impacts capability to understand the subject information and to provide conscious informed consent in the discretion of the investigator / study personnel
  • •Objections of the investigator to the subject's participation in the trial due to medical reasons or any other reason for which the subject should not participate in the opinion of the investigator
  • •Participation in any clinical investigation with systemic and/or pharmaceutical substances within the last 4 weeks and/or in parallel
  • •Sponsors, manufacturers or CRO staff

研究组 & 干预措施

TENA-PROTO1

Experimental

Investigational device. Early prototype

干预措施: TENA-PROTO1 (Device)

结局指标

主要结局

Bladder detectability rate as a function of gender, BMI, age, sensor position, posture and combinations of these variables

时间窗: 4 months

Percentage of those, where the bladder was detected in total or regarding different subgroups (BMI, age, sex, postural positions and sensor location ) based on raw measurement data of the urinary bladder region of volunteers with the early prototype of the Bladder Sensor in multiple postural positions to evaluate the detectability of the bladder in the intended users

Raw measurement data for the development of an algorithm to determine the bladder filling status

时间窗: 4 months

Raw data, that has been assessed by the prototype (TENA-PROTO1) will be used to develop a product specfic algorithm (R\&D outcome)

次要结局

  • Evaluation of the fixation methods and device regarding user needs by the subjects on a score(4 months)
  • Any adverse event (AE) or device deficiency (DD)(Ongoing documentation after enrolment until end of the measurement day (4 months))

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验